Getinge AB agreed to acquire Paragonix Technologies Inc. for $477 million, including upfront and earn out payments. The deal marks Getinge’s entry into the global organ preservation and transportation market, a rapidly advancing field driven by rising transplant volumes, technological innovations and evolving clinical practices. Read More
Medtronic plc hit a sweet spot with its diabetes devices, with the unit leading the company in growth in its first quarter 2025 results. Diabetes device sales grew 11.8% to $647 million for the quarter, an important boost that pushed total revenue up to $7.9 billion ($8.01 billion, adjusted), a 2.8% reported increase or 5.3% exchange rate impact. No other unit saw more than single-digit increases in sales. Read More
Quantamatrix Inc. is advancing an Ultra-Rapid Antimicrobial Susceptibility Testing sepsis diagnostic test, touted as having the world’s fastest all-in-one antimicrobial technology, to reduce sepsis diagnosis time from days to an average of 13 hours. Read More
TGA opened a consultation for regulation of assistive technologies, a key element of which is to make determinations about the regulatory status of some of these products. While the agency makes clear that some items that are currently unregulated may soon be subject to regulation, one of the more innocuous-seeming articles that may fall under regulation is the common and seemingly innocuous wig. Read More
The long struggle by Boston-based I2o Therapeutics Inc.’s business unit Intarcia Therapeutics to get long-lasting exenatide for diabetes onto the market ended with a final thumbs-down from the U.S. FDA because of safety concerns. At issue was ITCA-650, a twice-yearly implantable exenatide-device combo meant to improve glycemic control in adults with type 2 diabetes. Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Applied DNA, Medrhythms, Melzi Corp., Spartan Medical. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aisap, Qure.ai, Neurocare. Read More
